Long-Acting Slow Effective Release Antiretroviral Therapy (LASER ART)

LASER ART opens powerful option for HIV treatment

  • Sustained delivery of antiretroviral drugs
  • Increased penetration into viral reservoirs
  • Decreased dosing for ART therapy
  • Less frequent dosing for ART therapy


Licensing Manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-559-2166.


LASER ART opens powerful option for HIV treatment

Howard Gendelman, M.D. (LASER ART)

Howard Gendelman, M.D.

Managing HIV treatment may never be the same.
Researchers at the University of Nebraska Medical Center have discovered a way to revolutionize the treatment of HIV. Early studies show UNMC’s novel approach could reduce the regimen to a single treatment once every month, eliminating the need for current strategies that require daily administration of medicine.
Antiretroviral therapies, or ART, are also ineffective at reaching viral reservoirs such as the lymph nodes and the central nervous system. These viral reservoirs essentially serve as a bunkers that shelter HIV from current medications. But UNMC researchers overcame this obstacle with a new nanoformulation called LASER ART.
LASER ART harnesses the power of the patient’s immune system to store and deliver ART medications throughout the entire body in a sustained release formulation.
LASER ART targets the immune system’s hunter cells, or macrophages, which roam the body on a perpetual seek and destroy mission looking for foreign invaders. LASER ART piggybacks on the macrophages, which have full access to all parts of the body, including the central nervous system—a particularly difficult system to hack for most modern medicines.
Early tests on mouse models and large animals show that LASER ART produces a sustained release with long-lasting antiretroviral activity.
With further development LASER ART could have a dramatic impact on the estimated 34.2 million people on the planet who are affected by HIV. The Centers for Disease Control estimates 1.1 million Americans are living with HIV infection.
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.

Additional Information

PublicationsTechnical DetailsMedia Coverage


TopMedia CoveragePublications

Technical Details

Antiretroviral Therapy for the Treatment of HIV
HIV is a major health threat that affects over 35 million people worldwide with over 50,000 new infections per year in the US alone. With the advent of antiretroviral therapy (ART), the management of HIV has greatly improved over the years. Despite this improvement many of the drugs used in ART cocktails have limited capacity to gain access to viral reservoirs in areas such as the lymph nodes and central nervous system.
Current therapies require patients to take their medication daily and some of these therapies have significant side effects. Therefore it has been suggested that the development of a long acting ART formulation could greatly improve patient adherence to ART and also allow greater access to viral reservoirs.
Researchers at the University of Nebraska Medical Center have developed targeted long acting nanoformulations of ART called LASER ART. LASER ART is comprised of a polymeric shell that encapsulates the desired drug. The polymers can be conjugated to a variety of targeting moieties to enhance delivery of the drugs to specific cells and/or tissues.
Current LASER ART formulations are be developed to specifically deliver the ART directly to macrophages which can then distribute the drugs throughout the body including into viral reservoirs. LASER ART has been tested in various in vitro and in vivo systems. PK/PD studies have been conducted in mice. These PK studies have demonstrated that LASER ART formulations are capable of releasing drugs (at therapeutic levels) for at least one month. Furthermore, these formulations also significantly increase drug levels in key tissues and viral reservoirs such as the lymph nodes. LASER ART formulations have also been tested in various mouse models of HIV infection. The LASER ART technology should allow for formulations that could be administered every three to six months, or perhaps longer.
We are actively pursuing the development of targeted LASER ART formulations for clinical use. We are interested in pursuing industry collaborations to develop LASER ART formulations for a variety of HIV drugs.
TopPublicationsTechnical Details

Media Coverage

  • “‘A cure of HIV is possible’: UNMC, Temple researchers eliminate virus in humanized mice,” Omaha World-Herald
  • “Researchers say they’re closer to finding cure for HIV after using CRISPR technology to eliminate disease in live mice for the first time,” CNBC
  • “CRISPR gene-editing ‘eliminates’ HIV in some mice. What does it mean for humans?,” PBS NewsHour
  • “For the First Time, Researchers Eliminated HIV From the Genomes of Living Animals,” Time
  • “Researchers have eliminated HIV in mice for the first time. Is a cure for humans next?,” USA Today/Yahoo
  • “Researchers eliminated HIV from the DNA of infected mice. It’s the first step toward a cure for humans, they say,” CNN
  • “HIV patients could undergo genetic editing within year to snip away virus ,” London Telegraph
  • “Researchers announce a breakthrough HIV cure in mice,” CBS News

TopPublicationsTechnical DetailsMedia Coverage